Literature DB >> 33735314

Deletion of arginase 2 attenuates neuroinflammation in an experimental model of optic neuritis.

Amritha A Candadai1,2,3, Fang Liu1,2,3,4, Abdelrahman Y Fouda2,3,4, Moaddey Alfarhan1,2,3, Chithra D Palani1,2,4, Zhimin Xu2,4, Ruth B Caldwell2,4,5, S Priya Narayanan1,2,3,4,5.   

Abstract

Vision impairment due to optic neuritis (ON) is one of the major clinical presentations in Multiple Sclerosis (MS) and is characterized by inflammation and degeneration of the optic nerve and retina. Currently available treatments are only partially effective and have a limited impact on the neuroinflammatory pathology of the disease. A recent study from our laboratory highlighted the beneficial effect of arginase 2 (A2) deletion in suppressing retinal neurodegeneration and inflammation in an experimental model of MS. Utilizing the same model, the present study investigated the impact of A2 deficiency on MS-induced optic neuritis. Experimental autoimmune encephalomyelitis (EAE) was induced in wild-type (WT) and A2 knockout (A2-/-) mice. EAE-induced cellular infiltration, as well as activation of microglia and macrophages, were reduced in A2-/- optic nerves. Axonal degeneration and demyelination seen in EAE optic nerves were observed to be reduced with A2 deletion. Further, the lack of A2 significantly ameliorated astrogliosis induced by EAE. In conclusion, our findings demonstrate a critical involvement of arginase 2 in mediating neuroinflammation in optic neuritis and suggest the potential of A2 blockade as a targeted therapy for MS-induced optic neuritis.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33735314      PMCID: PMC7971528          DOI: 10.1371/journal.pone.0247901

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  82 in total

Review 1.  Cytokines: powerful regulators of glial cell activation.

Authors:  Gareth R John; Sunhee C Lee; Celia F Brosnan
Journal:  Neuroscientist       Date:  2003-02       Impact factor: 7.519

Review 2.  Are current disease-modifying therapeutics in multiple sclerosis justified on the basis of studies in experimental autoimmune encephalomyelitis?

Authors:  Nasr Farooqi; Bruno Gran; Cris S Constantinescu
Journal:  J Neurochem       Date:  2010-10-07       Impact factor: 5.372

Review 3.  Macrophage activation and polarization.

Authors:  Fernando Oneissi Martinez; Antonio Sica; Alberto Mantovani; Massimo Locati
Journal:  Front Biosci       Date:  2008-01-01

4.  Calcitonin gene-related peptide decreases IL-1beta, IL-6 as well as Ym1, Arg1, CD163 expression in a brain tissue context-dependent manner while ameliorating experimental autoimmune encephalomyelitis.

Authors:  Ilaria Rossetti; Laura Zambusi; Annamaria Finardi; Antonella Bodini; Luciano Provini; Roberto Furlan; Stefano Morara
Journal:  J Neuroimmunol       Date:  2018-07-25       Impact factor: 3.478

5.  Suppression of EAE and prevention of blood-brain barrier breakdown after vaccination with novel bifunctional peptide inhibitor.

Authors:  Ahmed H Badawi; Paul Kiptoo; Wen-Tung Wang; In-Young Choi; Phil Lee; Charlotte M Vines; Teruna J Siahaan
Journal:  Neuropharmacology       Date:  2011-12-17       Impact factor: 5.250

6.  F4/80, a monoclonal antibody directed specifically against the mouse macrophage.

Authors:  J M Austyn; S Gordon
Journal:  Eur J Immunol       Date:  1981-10       Impact factor: 5.532

7.  Genomic scale profiling of autoimmune inflammation in the central nervous system: the nervous response to inflammation.

Authors:  Ruaidhrí J Carmody; Brendan Hilliard; Kimberly Maguschak; Lewis A Chodosh; Youhai H Chen
Journal:  J Neuroimmunol       Date:  2002-12       Impact factor: 3.478

Review 8.  Re-evaluating the treatment of acute optic neuritis.

Authors:  Jeffrey L Bennett; Molly Nickerson; Fiona Costello; Robert C Sergott; Jonathan C Calkwood; Steven L Galetta; Laura J Balcer; Clyde E Markowitz; Timothy Vartanian; Mark Morrow; Mark L Moster; Andrew W Taylor; Thaddeus W W Pace; Teresa Frohman; Elliot M Frohman
Journal:  J Neurol Neurosurg Psychiatry       Date:  2014-10-29       Impact factor: 10.154

9.  Transgenic inhibition of astroglial NF-κB protects from optic nerve damage and retinal ganglion cell loss in experimental optic neuritis.

Authors:  Roberta Brambilla; Galina Dvoriantchikova; David Barakat; Dmitry Ivanov; John R Bethea; Valery I Shestopalov
Journal:  J Neuroinflammation       Date:  2012-09-10       Impact factor: 8.322

10.  Arginase 2 deficiency reduces hyperoxia-mediated retinal neurodegeneration through the regulation of polyamine metabolism.

Authors:  S P Narayanan; Z Xu; N Putluri; A Sreekumar; T Lemtalsi; R W Caldwell; R B Caldwell
Journal:  Cell Death Dis       Date:  2014-02-20       Impact factor: 8.469

View more
  3 in total

1.  Neuroprotective Effects of Fingolimod in a Cellular Model of Optic Neuritis.

Authors:  Amritha A Candadai; Fang Liu; Arti Verma; Mir S Adil; Moaddey Alfarhan; Susan C Fagan; Payaningal R Somanath; S Priya Narayanan
Journal:  Cells       Date:  2021-10-28       Impact factor: 6.600

Review 2.  Regulating Polyamine Metabolism by miRNAs in Diabetic Cardiomyopathy.

Authors:  Tyler N Kambis; Hadassha M N Tofilau; Flobater I Gawargi; Surabhi Chandra; Paras K Mishra
Journal:  Curr Diab Rep       Date:  2021-12-13       Impact factor: 4.810

3.  Pharmacological Inhibition of Spermine Oxidase Suppresses Excitotoxicity Induced Neuroinflammation in Mouse Retina.

Authors:  Moaddey Alfarhan; Fang Liu; Shengshuai Shan; Prahalathan Pichavaram; Payaningal R Somanath; S Priya Narayanan
Journal:  Int J Mol Sci       Date:  2022-02-15       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.